It was recently announced that IsoTis S.A., a Swiss orthobiologics company, obtained a U.S. patent on bone tissue repair. U.S. Patent No. 7,132,110, entitled “Tissue repair compositions and methods for their manufacture and use,” was issued this month to IsoTis OrthoBiologics, Inc., and includes 86 composition and method claims on the preparation of an osteogenic compound for the treatment of damaged bone tissue. According to the patent, “[a]n osteogenic composition is prepared by a process including the steps of subjecting demineralized bone to an extraction medium to produce an insoluble extraction product and a soluble extraction product, separating the insoluble extraction product and the soluble extraction product, drying the soluble extraction product to remove all or substantially all of the moisture in the soluble extraction product, and combining the dried soluble extraction product [] with demineralized bone particles.” This technology addresses the “need in the art for additional tissue repair compositions that employ tissue repair factors that are substantially freed of the cross-linked DBM [demineralized bone matrix] collagen network and that do not require complicated extraction and purification steps.”

U.S. Patent No. 7,132,110: LINK
IsoTis Press Release: LINK
IsoTis Website: LINK
Yahoo! News Article: LINK